Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:BCDA NASDAQ:CSCI NASDAQ:PBM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$0.43-0.7%$0.44$0.30▼$3.33$12.75M-1.231.69 million shs479,125 shsBCDABioCardia$2.26-0.9%$2.23$1.63▼$4.66$12.55M0.81274,396 shs46,014 shsCSCICOSCIENS Biopharma$3.77+5.1%$3.53$1.96▼$6.77$11.30M0.7611,084 shs19,334 shsPBMPsyence Biomedical$5.21-2.1%$4.88$2.92▼$699.19$3.02M0.22113,816 shs14,058 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-4.91%-11.24%+42.16%+12.59%-81.86%BCDABioCardia-2.15%-0.44%+4.59%+19.37%-35.59%CSCICOSCIENS Biopharma-5.08%-5.86%-3.75%+21.84%+343,599,900.00%PBMPsyence Biomedical-2.24%+1.75%+15.42%+41.45%-97.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals2.5654 of 5 stars3.53.00.00.03.31.70.0BCDABioCardia3.6076 of 5 stars3.83.00.00.04.42.50.6CSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence Biomedical0.9841 of 5 stars0.03.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 3.00Buy$8.001,757.87% UpsideBCDABioCardia 3.50Strong Buy$25.001,006.19% UpsideCSCICOSCIENS Biopharma 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PBM, ACXP, BCDA, and CSCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$8.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/ABCDABioCardia$60K207.17N/AN/A$0.18 per share12.56CSCICOSCIENS Biopharma$9.59M1.24N/AN/A$3.49 per share1.08PBMPsyence BiomedicalN/AN/A$1.75 per share2.98$11.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$0.70N/AN/AN/AN/A-526.78%-223.78%8/8/2025 (Estimated)BCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)PBMPsyence Biomedical$1.01MN/A0.00∞N/AN/AN/AN/AN/ALatest PBM, ACXP, BCDA, and CSCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ACXPAcurx Pharmaceuticals-$0.10N/AN/AN/AN/AN/A5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/12/2025Q1 2025ACXPAcurx Pharmaceuticals-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A1.931.93BCDABioCardiaN/A0.360.36CSCICOSCIENS BiopharmaN/A2.882.54PBMPsyence BiomedicalN/A11.0411.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%BCDABioCardia20.57%CSCICOSCIENS Biopharma0.73%PBMPsyence Biomedical77.44%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals26.00%BCDABioCardia20.00%CSCICOSCIENS Biopharma0.10%PBMPsyence Biomedical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals329.41 million21.76 millionOptionableBCDABioCardia405.50 million4.40 millionOptionableCSCICOSCIENS Biopharma203.15 million3.14 millionN/APBMPsyence BiomedicalN/A570,000548,000N/APBM, ACXP, BCDA, and CSCI HeadlinesRecent News About These CompaniesPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesJune 18, 2025 | globenewswire.comPsyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025June 18, 2025 | newsfilecorp.comNPsyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | finanznachrichten.dePsyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | newsfilecorp.comNCVS Sues Arkansas Over Law Banning PBM Ownership Of PharmaciesMay 29, 2025 | forbes.comPsyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialMay 27, 2025 | newsfilecorp.comNPsyence Biomedical Ltd. WtMay 21, 2025 | marketwatch.comPsyence Biomedical Advances Psilocybin Drug Development as of May 2025May 20, 2025 | tipranks.comPsyence Biomedical announces reverse stock splitMay 2, 2025 | investing.comPsyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock SplitMay 1, 2025 | newsfilecorp.comNPsyence Group consolidates its sharesApril 18, 2025 | greenmarketreport.comGPsyence BioMed gets Nasdaq notice for non-complianceApril 18, 2025 | msn.comPsyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 17, 2025 | newsfilecorp.comNPsyence Group Inc.: Psyence Group Announces Share ConsolidationApril 17, 2025 | finanznachrichten.dePsyence Group Announces Share ConsolidationApril 17, 2025 | globenewswire.comPsyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply dealApril 16, 2025 | greenmarketreport.comGPsyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementApril 15, 2025 | newsfilecorp.comNPsyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in AustraliaApril 8, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBM, ACXP, BCDA, and CSCI Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$0.43 0.00 (-0.69%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.01 (+1.72%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.BioCardia NASDAQ:BCDA$2.26 -0.02 (-0.88%) Closing price 04:00 PM EasternExtended Trading$2.27 +0.01 (+0.49%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.COSCIENS Biopharma NASDAQ:CSCI$3.77 +0.18 (+5.13%) Closing price 03:54 PM EasternExtended Trading$4.00 +0.23 (+6.12%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Psyence Biomedical NASDAQ:PBM$5.21 -0.11 (-2.07%) Closing price 03:56 PM EasternExtended Trading$5.30 +0.09 (+1.73%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
